selected scholarly activity
-
conferences
- Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP. Blood. 3734-3736. 2022
- Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Blood. 1934-1941. 2019
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 917-917. 2011
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy. Blood. 566-566. 2009
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial.. Blood. 954-955. 2008
- A phase II study of ZD6474, a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with relapsed multiple myeloma (MM).. Blood. 944A-944A. 2004
- The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation. Blood. 983A-983A. 2003
- Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin’s or Hodgkin’s lymphoma. International Journal of Radiation Oncology Biology Physics. 166-171. 2003
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma. 39-48. 2003
- Survival of patients with acute leukemia after bone marrow transplantation using allografts depleted of T-cells by counterflow centrifugal elutriation (CCE).. Blood. 379B-379B. 2001
- A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma.. Blood. 846A-846A. 2000
- Allogeneic bone marrow transplantation (allo BMT): Role of T cell depletion (TCD) and graft versus host disease (GVHD).. Blood. 202A-202A. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?. Blood. 132A-132A. 2000
- Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes.. Blood. 335B-335B. 2000
- An Outbreak of Vancomycin-Dependent Enterococcus faecium in a Bone Marrow Transplant Unit. Clinical Infectious Diseases. 1268-1273. 1999
- Analysis of engraftment in a randomized trial of 4hydroperoxycyclophosphamide (4HC) purged autologous bone marrow transplant (ABMT) in patients with lymphoid malignancies: Preliminary analysis of engraftment.. Blood. 460A-460A. 1998
- Autologous bone marrow transplantation (ABMT) with 4-hydroperoxycyclophosphamide (4HC) purging as treatment for indolent non-Hodgkins lymphoma (NHL).. Blood. 463A-463A. 1998
- Fludarabine and cyclophosphamide: A highly active and well tolerated regimen for patients with previously untreated indolent lymphomas.. Blood. 413A-413A. 1998
- In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHM.. Blood. 648A-648A. 1998
- Preparative regimens in bone marrow transplantation: An analysis of outcomes in 1174 patients.. Blood. 129A-129A. 1998
- Using engineered allografts to improve transplant outcome in multiple myeloma (MM).. Blood. 992-992. 1997
- Psychological Distress Among Adult Patients Being Evaluated for Bone Marrow Transplantation. Journal of the Academy of Consultation-Liaison Psychiatry. 10-19. 1997
- Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: Response rates and toxicity.. Blood. 2345-2345. 1996
- Changes in quality of life during the first year after bone marrow transplantation: A prospective study.. Blood. 1582-1582. 1995
- Etretinate: A novel agent for the treatment of refractory sclerodermatous chronic graft versus host disease.. Blood. 1579-1579. 1995
- Low risk of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) in patients receiving elutriated allogeneic marrow transplants may reflect depletion of EBV infected lymphocytes from the graft.. Blood. 2490-2490. 1995
- EXPLOSIVE GRAFT-VERSUS-HOST DISEASE. Blood. A422-A422. 1993
- TREATMENT OF REFRACTORY SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE WITH ETRETINATE. Experimental Hematology. 1106-1106. 1993
- Eligible-non-randomized patients: Their impact on generalizability. Contemporary Clinical Trials. 391-391. 1992
- GENERALIZABILITY OF THE RESULTS OF A TRIAL OF RADIATION-THERAPY IN BREAST-CANCER. Clinical Research. A370-A370. 1992
- HYPERFINE INTERACTION TENSORS FOR WEAKLY COUPLED PROTONS. Bulletin of the American Physical Society. 832-+. 1971
-
journal articles
-
Outcomes of
MYC ‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroupSWOG S9704. British Journal of Haematology. 174:686-691. 2016 - Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. New England Journal of Medicine. 369:1681-1690. 2013
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 121:1517-1523. 2013
- Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia. 13:19-24. 2013
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 118:2091-2091. 2011
- Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 29:8001-8001. 2011
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.. Blood. 114:1390-1390. 2009
- Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma. Blood. 112:4332-4332. 2008
- Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial. Blood. 112:2767-2767. 2008
- A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Investigational New Drugs. 24:529-535. 2006
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).. Blood. 104:3464-3464. 2004
- Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma. Cancer. 101:1835-1842. 2004
- Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age. Bone Marrow Transplantation. 32:1135-1143. 2003
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Transplantation and Cellular Therapy. 9:312-319. 2003
- Cancer problems in living and quality of life after bone marrow transplantation. Journal of Clinical Psychology in Medical Settings. 10:27-34. 2003
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma. Leukemia and Lymphoma. 44:29-37. 2003
- Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD). Blood. 96. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. Blood. 96. 2000
- Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplantation. 26:1179-1184. 2000
- Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Transplantation and Cellular Therapy. 6:628-632. 2000
- Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplantation. 24:637-640. 1999
- Etretinate Therapy for Refractory Sclerodermatous Chronic Graft-Versus-Host Disease. Blood. 93:66-70. 1999
- Etretinate Therapy for Refractory Sclerodermatous Chronic Graft-Versus-Host Disease. Blood. 93:66-70. 1999
- CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplantation. 22:947-955. 1998
- CD34 Augmentation Improves Allogeneic T Cell-Depleted Bone Marrow Engraftment. Stem Cells and Development. 7:151-157. 1998
- Preparative regimens in bone marrow transplantation: An analysis of outcomes in 1174 patients. International Journal of Radiation Oncology Biology Physics. 42:194-194. 1998
- An outbreak of variably vancomycin dependent enterococcus. Clinical Infectious Diseases. 25:363. 1997
- Graft-versus-host disease. Current Opinion in Oncology. 9:131-138. 1997
- Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant.. Journal of Clinical Oncology. 14:1327-1332. 1996
- Quality of life and social support of patients being evaluated for bone marrow transplantation. Journal of Clinical Psychology in Medical Settings. 2:357-372. 1995
- BOOK REVIEW. Journal of the National Cancer Institute. 86:1641-1641. 1994
- Adjuvant radiotherapy for early breast cancer: patterns of practice in Ontario.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 149:1273-1277. 1993
- Comparison of the addition of T and N integer scores with TNM stage groups in head and neck cancer. Head and Neck. 15:497-503. 1993
- Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.. Bone Marrow Transplantation. 7:183-191. 1991
- Structural study of sulfamic acid at 4.2 K by ENDOR-detected NMR. Journal of Chemical Physics. 74:179-183. 1981
- The ascent of man: deductions based on a multivariate analysis of the brain.. Brain, Behavior and Evolution. 11:179-213. 1975
- SURVEY OF ATTITUDES OF PARENTS OF CHILDREN WITH CEREBRAL PALSY IN WINDSOR AND ESSEX COUNTY ONTARIO. CANADIAN MEDICAL ASSOCIATION JOURNAL. 95:1242-+. 1966
-
Outcomes of